US FDA grants futibatinib Breakthrough Therapy Designation for treatment of previously-treated advanced cholangiocarcinoma

The FGFR inhibitor in intended for use in patients with locally advanced or metastatic cholangiocarcinoma harbouring FGFR2 gene rearrangements, including gene fusions. The designation is based on data from the Phase II FOENIX-CCA2 study.

Source:

Biospace Inc.